AK105 and anlotinib for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Nov 2021: Trial registered, NCT05137171
  2. 2 May 2022: Trial started, NCT05137171

The trials

NCT05137171: AK105 Combined With Anlotinib in Patients With Cervical Cancer

State
Under way
Phase
Phase 2
People
36 planned
Started
2 May 2022
Primary completion
1 Jul 2025
Arms
AK105 and anlortinib
Results
None posted
  1. 30 Nov 2021: Trial registered
  2. 2 May 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.